Clinical trials: Stage D0 Prostate Cancer
Prostatic Neoplasms, Neoplasms of Prostate
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Background: Few studies or literature are available about the long-term safety of repeated peptide vaccinations in people over a period of time. Long-term vaccination may be needed to control tumors.
- Conditions
- Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer, Cancer Of Prostate
- Trial name
- NCT02362464
- Testing
- Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)